From: Mesenchymal stem cell therapy for doxorubicin cardiomyopathy: hopes and fears
Cell-based therapy hypothesis | Cell type/type of transplantation | Number of cells administered | Delivery route/ time of administration | Animal model | Doxorubicin treatment/ route of administration | Method of cardiac diagnosis | Increase in LVEF versus control (percentage) | References |
---|---|---|---|---|---|---|---|---|
Regeneration | BMMSC/autologous | 1 × 107 | Intracoronary/4 weeks after Dox treatment | Rabbit | 2 mg/kg per week for 8 weeks/intraperitoneal | Echocardiography | 3 (not significant) | [60] |
Regeneration | BMMSC/autologous | 1.5-2.0 × 106 | Epimyocardial/2 weeks after Dox treatment | Rabbit | 3 mg/kg for 6 weeks/intraperitoneal | Echocardiography | 9 (P < 0.002) | [61] |
Regeneration | BMMSC/heterologous | 5 × 106 | Intravenously/2 weeks after Dox treatment | Rat | Three doses of 2.5 mg/kg per week for 2 weeks/intraperitoneal | ND |  | [62] |
Regeneration | BMMSC/ heterologous | 5 × 106 | Intravenously (one injection per day, 10 times)/ 10 weeks after Dox treatment | Rat | 2.5 mg/kg per week for 6 weeks/intraperitoneal | Echocardiography | 13 (P < 0.05) | [63] |
Regeneration | hUCB/xenograft | 2.5 × 106 | Intravenously/2 week after Dox treatment | Mice | 400 ng/kg per minute/oral | ND |  | [49] |
Prevention | hUCB/xenograft | 1 × 106 | Intravenously/at the end of each Dox cycle | Mice | Three cycles of three doses of 2 mg/kg per week/intraperitoneal | Echocardiography | 10 (P < 0.05) | [64] |
Prevention | ASC/heterologous | 3 × 106 | Intravenously/3 days before Dox treatment | Rat | 5 mg/kg per week for 4 weeks/intraperitoneal | Echocardiography | 13 (not significant) | [65] |